Thyroid hormone (TH) treatment exerts beneficial effects on the cardiovascular system: it lowers cholesterol and LDL levels and enhances cardiac contractile function. However, little is known about the effect of TH on vascular function or the functional role of TH receptors (TRs) in the regulation of vascular tone. We have investigated the contribution of TRs to vascular contractility in the heart. Among different TR subtypespecific knockout (KO) mice, vascular contraction was significantly enhanced in coronary arteries isolated from TR␣ KO compared with wild-type mice, while chronic TH treatment significantly attenuated coronary vascular contraction. We found that TR␣ is the predominant TR in mouse coronary smooth muscle cells (SMCs). Coronary SMCs isolated from TR␣ KO mice exhibited a significant decrease in K ϩ channel activity, whereas TH treatment increased K ϩ channel activity in a dose-dependent manner. These data suggest that TR␣ in SMCs has prominent effects on regulation of vascular tone and TH treatment helps decrease coronary vascular tone by increasing K ϩ channel activity through TR␣ in SMCs. vascular contraction; coronary artery; knockout mouse; potassium channel THERE IS INCREASING EVIDENCE that the levels of thyroid hormone (TH) and/or TH nuclear receptors (TRs) are decreased in human patients and animal models with heart failure, myocardial infarction, and cardiac hypertrophy and in coronary bypass surgery patients (17, 22, 23, 26, 48, 49, 51) . TH treatment, therefore, exerts beneficial effects in these patients by enhancing cardiac contractile function as well as lowering cholesterol and LDL levels (24, 26, 39 -41). We recently reported that TR␤ in vascular endothelial cells (ECs) plays a crucial role in new vessel formation in hypertrophied hearts and triiodothyronine (T 3 ) treatment has beneficial effects on capillary network formation in ECs in vitro and in vivo. However, the effect of TH treatment on coronary vascular tone and the functional role of TRs in coronary smooth muscle cells (SMCs) were not explored, and this is the objective of the present study.
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TH action is classified as follows: 1) transcriptional activation via binding to nuclear TRs, followed by binding to TH response elements in target genes, and 2) extranuclear action, which is referred to as acute nongenomic action. The target genes regulated by TH have been well studied in cardiomyocytes; they include ion transport channels (e.g., voltage-gated K ϩ channels and Na ϩ /Ca 2ϩ exchanger) (for reviews see Refs. 5 and 24). Nuclear receptor-mediated TH action and acute nongenomic TH action regulate the functions of cardiomyocytes by increasing inotropy and chronotropy through modulation of Na ϩ , K ϩ , and Ca 2ϩ channel activity (57) . Chronic change in TH status alters cardiac function as well as systemic vascular resistance, as seen in patients with hyperthyroidism, who tend to exhibit tachycardia, decreased systemic vascular resistance, and increased left ventricular contractility, and in patients with hypothyroidism, who tend to exhibit bradycardia and slightly increased blood pressure (21, 24, 47) .
Coronary blood flow and coronary vascular resistance are tightly controlled by vascular tone and vascular density. Insufficient blood supply in the heart, caused by increased coronary vascular tension and rarefaction, leads to heart damage, including cardiac ischemia. Vascular SMCs and ECs are major players in the regulation of vascular tension and vascular/ capillary density, and both are potential targets of TH in the vascular system. It has been demonstrated that T 3 relaxes vascular SMCs by releasing relaxing factors from vascular ECs (50) and/or via direct effect on SMCs (46, 50) , and the relaxation is assumed to result from acute and nongenomic action of TH on vascular cells. On the other hand, genomic action of TH on vascular SMC function is less well understood. TH regulates gene transcription via binding to TRs. Two genes (TR␣ and TR␤) encode TRs, and at least two TR␣ isoforms (TR␣ 1 and TR␣ 2 ) and three TR␤ isoforms (TR␤ 1 , TR␤ 2 , and TR␤ 3 ) have been identified. TR␣ is predominant in most vascular cell types, including human coronary SMCs, aortic SMCs, and umbilical vein ECs (15, 37) . In the present study, we have the unique opportunity to use TR isoform-specific knockout (KO) mice to examine the effect of TR deletion on vascular contraction in coronary artery (CA) and to characterize the chronic TH effect on coronary SMCs in vivo.
MATERIALS AND METHODS
Reagents. M199, antibiotic reagents, Hoechst 33342, and dispase II were purchased from Invitrogen (Carlsbad, CA); anti-CD31 antibody and growth supplement (GS) from BD Biosciences (San Jose, CA); collagenase II from Worthington Biochemical (Lakewood, NJ); antiactin antibody from Santa Cruz Biotechnology (Santa Cruz, CA); and NG2 antibody from Millipore (Billerica, MA). All other chemicals were obtained from Sigma-Aldrich (St. Louis, MO).
Animal preparation. Male NIH Swiss mice were purchased from Harlan Sprague Dawley (Indianapolis, IN) at 4 wk of age. Alzet osmotic minipumps (Durect, Cupertino, CA) were implanted subcutaneously, and T 3 (10.5 ng·g body wt Ϫ1 ·day Ϫ1 ) was administered for 4 wk. Plasma T3 levels were 66.1 Ϯ 3.7 and 70.6 Ϯ 3.4 ng/dl in control and T3-treated mice, respectively (n ϭ 7 in each group TR KO mice. TR␣1 KO (TR␣ KO) mice were generated in the laboratory of Dr. B. Vennstrom, as described previously (61) . TR␤ KO mice were generated in the laboratory of Dr. J. Samarut by deletion of exons 4 and 5 of the TR␤ gene (12) .
Normalizing T 3 levels in TR␤ KO mice. TR␤ KO and wild-type mice were fed iodine-deficient 0.15% 6-propyl-2-thiouracil (PTU) food pellets (Harlan-Teklad, Madison, WI) for 5 wk. During the 1st wk, the animals were fed the PTU diet to decrease their endogenous hyperthyroidism. During the remaining 4 wk, daily injections of T 3 were given in saline (3.5 ng/g body wt ip). After 4 wk of this treatment, animals were used for experiments.
Isolation of coronary vascular SMCs. Mouse coronary SMCs (MCSMCs) were isolated using a modification of previously described methods (32, 33) . Briefly, dissected hearts were minced and incubated with M199 containing 1 mg/ml collagenase II and 0.6 U/ml dispase II for 1 h at 37°C. The digested material was filtered through sterile 40-m nylon mesh and washed in 2% FCS-M199. Subsequently, the cells were incubated with Dynabeads (Invitrogen), which were prepared as follows: M-450 Epoxy Dynabeads were incubated with NG2 antibody at 20 g/100 l in 100 mM sodium borate buffer at 4°C for 2 days, washed with PBS containing 0.1% BSA, and incubated overnight at 4°C. The cell suspension was incubated with the beads for 30 min at 4°C; then the beads attached to SMCs were captured by a Dynal magnet (Invitrogen). Mouse coronary ECs (MCECs) were isolated as described elsewhere (32) .
Western blot analysis. Isolated SMCs and ECs were lysed and centrifuged at 16,000 g for 10 min at 4°C. Supernatants were used as a sample protein. Samples were separated through a SDS-polyacrylamide gel and transferred to nitrocellulose membranes. Blots were incubated with a primary antibody, anti-CD31 (an EC-specific marker, 1:1,000 dilution), anti-SM22 (an SMC-specific marker, 1:1,000 dilution), or anti-actin (a control peptide, 1:4,000 dilution), and then with secondary antibody. The immunoblots were detected with SuperSignal West Pico reagent (Thermo Fisher Scientific, Rockford, IL).
Immunofluorescence staining. Purity of the SMC population in cells isolated from hearts was tested by anti-␣-smooth muscle actin-Cy3 (SMA, a marker for SMCs) and Bandeiraea simplicifolia lectin-FITC (BS-1, a marker for ECs) staining in MCSMCs and MCECs. Cells were seeded on a cover glass in a four-well chamber and cultured in cell-specific media as follows: M199 supplemented with 10% FCS, 100 g/ml GS, 100 IU/ml penicillin, 100 g/ml streptomycin, and 50 mg/l D-valine (SMC medium) and M199 supplemented with 20% FCS, 100 g/ml GS, 100 IU/ml penicillin, 100 g/ml streptomycin, 50 mg/l D-valine, and 16 U/ml heparin (EC medium). Cells were stained with Hoechst (for nuclear staining, 1 g/ml) 30 min before they were fixed. Cells were fixed with 100% methanol at Ϫ20°C and incubated with BS-l (1:400 dilution) and SMA (1:400 dilution) for 1 h. The fluorescence images were captured by a charge-coupled device camera connected to a fluorescence microscope with a ϫ20 objective lens.
Assay of TR mRNA. TR isoform predominance in coronary SMCs from wild-type mice was measured by real-time PCR. RNA from SMCs was isolated using the RNeasy Plus Micro kit (Qiagen, Chatsworth, CA). Briefly, cells were lysed in Buffer RLT Plus by 10 passages through a 21-gauge needle, and RNA was purified according to the manufacturer's instructions. cDNA was made by reverse transcription of DNase-free RNA templates using random hexamers and SuperScript III (Life Technologies, Carlsbad, CA). Primers for TR␣1, TR␤, and the endogenous reference gene acidic ribosomal phosphoprotein P0 are described elsewhere (31) . Measurements were made in triplicate using 1 ng of template per well with an Applied Biosystems 7300 real-time PCR system. The efficiency-correlated cycle threshold (⌬CT) method was used to determine the level, in arbitrary units, of TR␣1 and TR␤ RNA relative to acidic ribosomal phosphoprotein P0 (3). The levels of TR␣1 and TR␤ were compared to determine the relative abundance of each receptor isoform transcript in the SMCs.
CA ring isometric tension measurement. Isometric tension in CAs was measured as previously described, with minor modifications (32) . Second-or third-order small CAs were dissected in Krebs-Henseleit solution, cleaned of any adherent connective tissue and cardiomyocytes, and cut into 1-to 1.5-mm segments. Rings were mounted in a wire myograph over 20-m wires, set at a resting tension of 0.1 g, and allowed to equilibrate at 37°C for 60 min, with intermittent washes every 20 min. After equilibration, CAs were treated with 40 mM K ϩ solution and then used for the vascular contraction experiment.
Electrophysiological measurements. Electrophysiological experiments were performed as previously described (27) . Whole cell and single-channel K ϩ currents were recorded from SMCs with an Axopatch 1D amplifier and a DigiData 1200 interface using patch-clamp techniques. Voltage stimuli were delivered from a holding potential of Ϫ70 mV using voltage steps from Ϫ80 to ϩ80 mV in 10-mV increments. All experiments were performed at room temperature (22-24°C). Cells were plated on coverslips and superfused with physiological salt solution containing (in mM) 141 NaCl, 4.7 KCl, 1.8 CaCl 2, 1.2 MgCl2, 10 HEPES, and 10 glucose (pH 7.4). The pipette (intracellular) solution for whole cell current recording contained (in mM) 135 KCl, 4 MgCl 2, 10 HEPES, and 5 Na2ATP (pH 7.2). For single-channel K ϩ current recording in cell-attached patches, the pipette (external) solution contained (in mM) 140 KCl, 4 MgCl 2, 10 HEPES, and 10 EGTA (pH 7.4).
Statistical analysis. Values are means Ϯ SE. Bonferroni's test for multiple statistical comparisons and Student's t-test for unpaired samples were carried out to identify significant differences. Differences were considered to be statistically significant when P Ͻ 0.05.
RESULTS

TR isoform levels in MCSMCs.
SMCs were isolated from hearts, as described above. The Western blot demonstrates high SM22 protein expression, but little CD31 expression, in the sample from MCSMCs and high CD31 protein expression, but very low SM22 expression, in the sample from MCECs. In addition, SMCs from mouse hearts also exhibit high purity of the SMC population determined by SMA staining without BS-1 signal (Fig. 1A) . With use of the same method, mouse coronary SMCs were isolated from control mice to determine the expression level of TR subtypes. SMCs were directly lysed, without culturing, and the TR isoform levels were measured by real-time PCR. As shown in Fig. 1B , MCSMCs express TR␣ 1 predominantly. This observation is in line with previously published data from different species (37) .
Effect of TR deletion on high-K ϩ -induced contraction in the CA. Isometric tension was measured in CA rings dissected from TR␣ KO and wild-type mice. Vascular contraction is shown as tension normalized by vessel length (mg/mm). As shown in Fig. 2, A and B-I, and B-II, high K ϩ significantly increased vascular contraction in CAs from TR␣ KO mice compared with CAs from wild-type mice. In the presence of 100 M N-nitro-L-arginine methyl ester (L-NAME, an endothelial NOS inhibitor) and 10 M indomethacin (a cyclooxygenase inhibitor), high-K ϩ -induced contraction was augmented in CAs from TR␣ KO and wild-type mice; however, the effect of inhibitors was more evident in CAs from TR␣ KO mice. These data imply that ECs from TR␣ KO mice release more relaxing factors to normalize the vasoconstriction enhanced in TR␣ KO mice. On the other hand, there is no significant difference in high-K ϩ -induced contraction in CAs from wild-type or TR␤ KO mice, regardless of the presence or absence of L-NAME and indomethacin (Fig. 2, B-III and B-IV) .
These data suggest that TR␣ plays a prominent role in the regulation of contractility in coronary vascular SMCs.
Effect of chronic T 3 administration on high-K ϩ -induced CA contraction. TH causes vascular relaxation ex vivo in a dosedependent manner, without affecting transcriptional activity in the nucleus (46, 50) . Here we examined whether chronic T 3 administration, without significant change in the plasma T 3 level, could alter the vascular response in CAs. At 4 wk after T 3 administration, CAs were dissected and high-K ϩ -induced contraction was compared in CAs from control and T 3 -treated mice. Figure 3A demonstrates that high-K ϩ -induced contraction was significantly decreased in CAs dissected from T 3 -treated mice, regardless of the absence or presence of L-NAME and indomethacin, implying that chronic T 3 administration attenuates vascular contractility by directly changing coronary SMC function (e.g., increasing K ϩ channel activity in SMCs).
High-K
ϩ -induced vascular contraction in TR␤ KO mice not made euthyroid. Systemic TR␤ deletion causes a significant increase in plasma T 3 (10, 12) . Thus it is necessary to normalize the T 3 level to avoid the excess T 3 action through TR␣ in TR␤ KO mice. We intentionally used TR␤ KO and wild-type mice without normalized T 3 levels to examine the T 3 effect only through TR␣. As seen in Fig. 3B , CAs from these TR␤ KO mice have significantly attenuated vascular constriction in response to high K ϩ , suggesting that T 3 attenuates the vascular contraction through TR␣ activation.
Effect of TR␣ deletion on whole cell K ϩ currents in coronary SMCs. To test whether augmented vascular contraction results from impaired K ϩ channel activity in TR␣ KO SMCs, we examined and compared the amplitude and kinetics of whole cell K ϩ currents in SMCs isolated from hearts of wild-type and TR␣ KO mice. As shown in Fig. 4 , the amplitude of the whole cell K ϩ currents was significantly attenuated in SMCs from TR␣ KO mice compared with SMCs from wild-type mice. On the basis of the current density at ϩ80 mV (Fig. 4B) , the amplitude of whole cell K ϩ currents, measured at the steady state of the currents, in TR␣ KO SMCs was ϳ62.5% of the magnitude in wild-type SMCs. These data suggest that augmented vasoconstriction in SMCs from TR␣ KO mice is due, at least in part, to the attenuated K ϩ channel activity in SMCs from TR␣ KO mice.
Effect of T 3 on K ϩ channel activity in coronary SMCs. There is increasing evidence that TH increases K ϩ channel activity via upregulation of K ϩ channel expression in cardiomyocytes (11, 34, 52, 59, 60) and other cell types (28, 43) , but little is known about the effect in vascular SMCs. To examine the effect of TH on K ϩ channel activity, we measured singlechannel (Fig. 5, A-F ) and whole cell (Fig. 5, G and H) K ϩ currents in control SMCs (0 nM T 3 ) and SMCs treated with T 3 (1 or 100 nM). Typical records of single-channel K ϩ currents and the results from whole cell K ϩ current experiments demonstrate that T 3 treatment markedly increased the K ϩ current in coronary SMCs (Fig. 5) . T 3 treatment significantly increased the steady-state open probability (Fig. 5, E and F) of the single-channel currents and the amplitude and current density (Fig. 5, G and H) of the whole cell currents, but did not affect the single-channel conductance (Fig. 5, C and D) . These data suggest that enhanced K ϩ channel activity, putatively by upregulated K ϩ channel expression, induces membrane hyperpolarization or repolarization of SMCs and, thus, attenuates vascular contraction in CAs in T 3 -treated mice.
DISCUSSION
The results of this study show that the deletion of TR␣ increases vascular contractility by attenuating K ϩ channel activity in coronary SMCs, while chronic T 3 administration decreases vascular contractility by increasing K ϩ current. TH administration has beneficial effects not only on cardiac function (17, 22-24, 26, 39 -41, 48, 49, 51) , but also on vascular function, including angiogenesis (33, 42, 58) . We recently reported that T 3 restores the microvascular density in the heart under pathological hypertrophy by upregulating mRNA and protein expression of TR␤ and VEGF receptor-2 (33). These effects of TH are primarily mediated through the activation of TRs followed by binding to specific DNA recognition sequences and inducing transcription of other genes. Although the regulation of vascular tone by TH has been demonstrated previously, most of these reports investigated the acute and nongenomic effects of TH (15, 18, 46, 50) . In the present study, we used TR isoform-specific KO mice and T 3 -treated mice to test the chronic effect of TH and TR deletion on the regulation of coronary vascular tone. As shown in Fig. 2 , TR␣ plays an important role in the regulation of vascular contractility in the CA. The reason why the deletion of TR␣ has pronounced effect on the vascular response and the deletion of TR␤ does not might be due to the predominant expression of TR␣ 1 in coronary SMCs (Fig. 1B) . Although most tissues express TR␣ and TR␤, vascular cells, including ECs and SMCs, and cardiomyocytes are known to exhibit strong expression of TR␣ (13, 15, 37, 53) , while cerebral cortical tissue expresses TR␤ as well as TR␣ (37) . TR␤ KO and wild-type . ECs were stained with Bandeiraea simplicifolia lectin-FITC (an EC marker, green), and nuclei were stained with Hoechst (blue). B: more TR␣1 than TR␤ mRNA expression in MCSMCs. Levels of TR␣1 and TR␤ mRNA expression were compared using real-time quantitative PCR in the same samples. T3, triiodothyronine. Values are means Ϯ SE (n ϭ 2). *P Ͻ 0.05. mice in Fig. 2 were fed a PTU diet and then treated with T 3 at the physiological concentration to normalize serum T 3 levels.
Membrane depolarization by high-K ϩ treatment increases cytosolic Ca 2ϩ concentration in SMCs, as well as ECs, through voltage-dependent ion channels (4, 9) . The increase of cytosolic Ca 2ϩ concentration in ECs initiates the production of endothelium-derived relaxing factors, including nitric oxide (NO) (2, 8, 35) . In TR␣ KO mice, concurrent inhibition of NO and prostacyclin strongly enhanced high-K ϩ -induced CA contraction, suggesting that ECs are releasing more NO and prostacyclin to mask augmented contraction in CAs from TR␣ KO mice (Fig. 2, B-II) . On the other hand, there is no significant change in high-K ϩ -induced contraction in the presence or absence of L-NAME and indomethacin in euthyroid TR␤ KO II and IV: contraction data in the presence of L-NAME and indomethacin. High K ϩ significantly increased contraction in CAs from TR␣ KO mice, and inhibition of nitric oxide and prostacyclin further increased high-K ϩ -induced contraction in TR␣ KO mice compared with age-matched wild-type mice. There is no significant difference in high-K ϩ -induced contraction between TR␤ KO and wild-type mice. Values are means Ϯ SE. Without indomethacin and L-NAME: wild-type for TR␣ KO (n ϭ 5), TR␣ KO (n ϭ 5), wild-type for TR␤ KO (n ϭ 3), and TR␤ KO (n ϭ 3); with indomethacin and L-NAME: wild-type for TR␣ KO (n ϭ 4), TR␣ KO (n ϭ 4), wild-type for TR␤ KO (n ϭ 3), and TR␤ KO (n ϭ 3). *P Ͻ 0.05. Fig. 3 . Chronic T3 treatment significantly attenuates high-K ϩ -induced vascular contraction (A), and excess plasma T3 decreases vascular contractility of CAs from TR␤ KO mice not made euthyroid (B). A: T3 was chronically administered using an osmotic minipump for 4 wk (10.5 ng·g body wt Ϫ1 ·day Ϫ1 sc). Values are means Ϯ SE. Without indomethacin and L-NAME: control (n ϭ 5) and T3 (n ϭ 5); with indomethacin and L-NAME: control (n ϭ 4) and T3 (n ϭ 4). *P Ͻ 0.05. B: CAs were dissected from wild-type mice and TR␤ KO mice not made euthyroid. Values are means Ϯ SE; n ϭ 3 for wild-type and TR␤ KO (experiment was performed in the absence of indomethacin and L-NAME). *P Ͻ 0.05. mice vs. wild-type mice. Since TR␣ is the predominantly expressed TR in MCECs (90.6 Ϯ 9.0% TR␣ and 9.4 Ϯ 0.2% TR␤), it was expected that endothelial function would also be affected by TR␣ deletion, but this was not the case. Our recent data also demonstrate the crucial role of TR␤ in new vascular formation in coronary ECs, despite low TR␤ expression in ECs (33) . Taken together, TR␤, but not TR␣, might prominently contribute to the EC function, regardless of the TR␤ expression level in ECs. Further experiments are required to define the role of TR␤ in the regulation of vascular tone through EC activation.
Chronic change of TH status has been shown to have significant effects on systemic blood pressure and vascular response (25, 38, 44, 54 -56) . In the present study, administration of a physiological dose of T 3 to mice for 4 wk did not affect serum T 3 concentrations significantly. As shown in Fig.  3A , CAs dissected from T 3 -treated mice exhibit significantly attenuated high-K ϩ -induced vascular contraction in the presence and absence of L-NAME and indomethacin. These data suggest that attenuated vascular contraction is the result of direct T 3 effects on SMC function. Although it has been reported that T 3 causes SMC relaxation without binding nuclear receptors (46, 50) , the attenuated vascular contraction by T 3 in the present study is not an acute effect of T 3 but, rather, the result of T 3 -induced changes in gene transcription in SMCs, on the basis of the absence of T 3 in the perfusate during the contraction experiment. Interestingly, we found significantly attenuated contraction of CAs from TR␤ KO mice Fig. 4 . Comparison of whole cell K ϩ current in coronary SMCs isolated from wild-type and TR␣ KO mice. A: representative whole cell K ϩ currents, elicited by 300-ms step depolarization at potentials of Ϫ80 to ϩ80 mV from a holding potential of Ϫ70 mV. B: averaged current density (I) at ϩ80 mV. Note significantly decreased K ϩ current in coronary SMCs from TR␣ KO mice. Values are means Ϯ SE; n ϭ 9 wild-type and 7 TR␣ KO. *P Ͻ 0.05 vs. Wt. ϩ currents elicited by 200-ms step depolarization at Ϫ80 to ϩ80 mV from a holding potential of Ϫ70 mV in control (0 nM) SMCs and SMCs treated with 1 nM and 100 nM T3. H: averaged current density at ϩ80 mV. T3 treatment significantly enhanced K ϩ current density in human coronary SMCs. Values are means Ϯ SE; n ϭ 6, 7, and 9 for 0, 1, and 100 nM, respectively. *P Ͻ 0.05. without normalized T 3 levels compared with wild-type mice (Fig. 3B) . In TR␤ KO mice, thyroid-stimulating hormone, thyroxine, and T 3 levels are extremely high, but there is no change in the T 3 level in TR␣ KO mice (12) . The excess T 3 in TR␤ KO mice stimulates TR␣, and TR␣-prominent phenotypes could be seen in TR␤ KO mice without normalized T 3 levels (19) . These data suggest that increased T 3 stimulates TR␣ and, subsequently, decreases vascular contraction in TR␤ KO mice without normalized T 3 levels and that attenuated vascular contractility in T 3 -treated mice might be due to T 3 action through TR␣.
TR␣ (11, 13, 34) , as well as serum TH (1, 16, 30, 45) , levels regulate K ϩ channel expression levels and K ϩ current in cardiomyocytes; however, little is known about the effect of TRs and TH on K ϩ channel activity in vascular SMCs. We demonstrate attenuated K ϩ channel activity of SMCs isolated from TR␣ KO mice compared with wild-type mice (Fig. 4) , whereas SMCs treated with T 3 exhibit significantly increased K ϩ current (Fig. 5) , suggesting that the change in vascular contractility might be due to the altered K ϩ channel activity in SMCs in TR␣ KO and T 3 -treated mice. To identify the changes in mRNA level of K ϩ channels, we first used a Microarray platform (University of California, San Diego, Biogem Core Facility, Illumina Sentrix Bead-Chip array) to screen the gene profiles in coronary SMCs from wild-type and TR␣ KO mice. Among 41 genes encoding K ϩ channel subunits on the chip, 4 are downregulated in TR␣ KO mice: KCNA1 (0.81-fold change), KCNB1 (0.58-fold change), KCNK3 (0.62-fold change), and KCNK5 (0.65-fold change). Next, using real-time PCR, we measured and compared mRNA expression level in coronary SMCs from wild-type and TR␣ KO mice. Among 10 tested genes, three K ϩ channel subunits show a trend for decreased expression in TR␣ KO mice (wild-type vs. TR␣ KO, n ϭ 4 in each group): KCNA1 (1.14 Ϯ 0.32 vs. 0.55 Ϯ 0.13), KCNA5 (1.08 Ϯ 0.24 vs. 0.87 Ϯ 0.17), and KCNMB1 (1.07 Ϯ 0.22 vs. 0.85 Ϯ 0.19). We further tested the mRNA level of four genes in coronary SMCs from control and T 3 -treated mice, and three of these genes show a trend for increased expression in T 3 -treated mice (control vs. T 3 , n ϭ 3 in each group): KCNA1 (1.08 Ϯ 0.26 vs. 1.58 Ϯ 0.06), KCNA4 (1.19 Ϯ 0.09 vs. 2.21 Ϯ 0.64), and KCNMB1 (1.03 Ϯ 0.16 vs. 1.77 Ϯ 0.39). On the basis of these data, we assume that KCNA1 and KCNMB1 might be the candidates that are regulated by TH stimulus and modulate coronary vascular tension by changing their channel activities in MCSMCs, although none of data show a significant difference between the control and model mice. K ϩ channel activators are widely used for treatment of patients with stroke, hypertension, cardiac ischemia, and so on (6, 14, 20, 36) . The question is whether TH can be used as a potential activator of K ϩ channels (by opening K ϩ channels or by upregulating K ϩ channel expression) in those patients. The TH concentration must be carefully chosen, and the effect on cardiac function must be monitored during TH administration, because high-dose TH increases heart rate and arrhythmia (7, 29, 41) . If TH is administered at a physiological concentration, it could play a beneficial role in the regulation of coronary vascular tone, in addition to its role in improving cardiac function and lowering cholesterol.
In conclusion, chronic T 3 administration increases K ϩ channel activity and decreases vascular contractility in CAs, while TR␣ in coronary SMCs plays a crucial role in regulating vascular tone.
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